Evidence map›Paper›PMID 40571857›Full record

ArticleImmunologic research2025

Immunomodulatory activity of 4-(Benzyloxy)phenol facilitates intracellular mycobacterial clearance through p53 mediated IL-35 signaling dependent JAK1/STAT3 pathway in human macrophages.

Lincoln Naik, Salina Patel, Mousumi Das, Dev Kiran Nayak, Pramathesh Kumar Dandsena, Mustafeez Ali Quaderi, Ashish Kumar, Amit Mishra, Ramandeep Singh, Abtar Mishra and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Immunologic research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Lincoln NaikLaboratory of Mycobacterial Immunology, Department of Life Science, National Institute of Technology, Rourkela, 769008, Odisha, India.
Salina PatelLaboratory of Mycobacterial Immunology, Department of Life Science, National Institute of Technology, Rourkela, 769008, Odisha, India.
Mousumi DasLaboratory of Mycobacterial Immunology, Department of Life Science, National Institute of Technology, Rourkela, 769008, Odisha, India.
Dev Kiran NayakLaboratory of Mycobacterial Immunology, Department of Life Science, National Institute of Technology, Rourkela, 769008, Odisha, India.
Pramathesh Kumar DandsenaLaboratory of Mycobacterial Immunology, Department of Life Science, National Institute of Technology, Rourkela, 769008, Odisha, India.
Mustafeez Ali QuaderiLaboratory of Mycobacterial Immunology, Department of Life Science, National Institute of Technology, Rourkela, 769008, Odisha, India.
Ashish KumarLaboratory of Mycobacterial Immunology, Department of Life Science, National Institute of Technology, Rourkela, 769008, Odisha, India.
Amit MishraCellular and Molecular Neurobiology Unit, Indian Institute of Technology Jodhpur, Rajasthan, 342011, India.
Ramandeep SinghTuberculosis Research Laboratory, Faridabad-Gurugram Expressway, Translational Health Science and Technology Institute, NCR Biotech Science Cluster, 3Rd Milestone, PO Box # 4, Faridabad, 121001, Haryana, India.
Abtar Mishra *Laboratory of Mycobacterial Immunology, Department of Life Science, National Institute of Technology, Rourkela, 769008, Odisha, India. avtar.mishra016@gmail.com.
Rohan Dhiman *Laboratory of Mycobacterial Immunology, Department of Life Science, National Institute of Technology, Rourkela, 769008, Odisha, India. dhimanr@nitrkl.ac.in.

Funding

Department of Biotechnology, Ministry of Science and Technology, India BT/PR42063/MED/29/1562/2021Department of Science and Technology (DST), Govt. of Odisha 4823/ST, Bhubaneswar (ST-SCST-MISC-0026-2020
6 · The paper itself

Abstract

Mycobacterium tuberculosis (M. tuberculosis), the causative agent of tuberculosis (TB), modulates host immune responses by regulating various cytokines. Precise regulation of these cytokines renders the host pathogen-free, whereas their dysregulation increases the susceptibility to infection. Hence, induction of host protective cytokines using immunomodulators to promote M. tuberculosis clearance has a rewarding impact in the context of TB treatment. This study explored the immunomodulatory activity of 4-(Benzyloxy)phenol (4-BOP) in mycobacteria infected differentiated THP-1 cells through IL-35 (an anti-inflammatory cytokine) production. Initially, we observed an increased mRNA and protein level expression of IL-35 and its cognate receptor upon 4-BOP treatment in mycobacteria-infected dTHP-1 cells. IL-35 receptor activation further led to phosphorylation of JAK1/STAT3, culminating in increased phagosome-lysosome fusion through elevation of intracellular Ca

Indexed as

Immunologic FactorsInterleukinsMacrophagesMycobacterium tuberculosisPhenolsTuberculosisTumor Suppressor Protein p53HumansJanus Kinase 1Signal TransductionSTAT3 Transcription FactorTHP-1 CellsImmunologic Factorsinterleukin-35, humanInterleukinsJAK1 protein, humanJanus Kinase 1PhenolsSTAT3 protein, humanSTAT3 Transcription FactorTumor Suppressor Protein p534-BOPCa2+IL-35JAK1/STAT3MycobacteriaPhagosome-lysosome fusion

Identifiers

PMID40571857

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.